Milestones

Incorporated

Signing of tech transfer with Biotherapy Institute of JAPAN, for the establishment of Immunotherapy (T cell and NK cell).

Collaboration with NCRM, INDIA for the establishment of Autologous stem cell therapy.

Awarded with Bionexus Status company

Accredited with Good Manufacturing Practice status certified by National Pharmaceutical Regulatory Agency (NPRA).

Support Clinical trial collaboration with IMR.

Study objective: Reconstruction of damaged corneas by transplantation of Autologous Limbal Epithelial Cells.

Collaborated with University Putra Malaysia (UPM) to explore Allogeneic MSCs product development.

Successfully developed a sustainable cryopreservation method for purified MSCs.

Pre-clinical project initiation for evaluation of safety & toxicity profile of NK cells.

Research collaboration with Malaysian University, University Sains Malaysia (USM) for the evaluation of NK cells efficacy in breast cancer induced rodent model.

Collaborated with University Teknology Malaysia (UiTM).

Study Title: Mechanism of the enhancement of immune cells sensitization and trafficking in osteosarcoma by adoptive immunotherapy in mice.

Fully supported Phase III Clinical Trial with Tessa Therapeutics, SINGAPORE .

Study objective: FDA registered A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma in 330 Patients.